Exchange: NASDAQ·Updated 07:34 PM EDT
News
all
press releases
Outlook Therapeutics, Inc. (OTLK) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Outlook Therapeutics, Inc. (OTLK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
More News
Lexicon Pharmaceuticals (LXRX) Reports Q2 Loss, Lags Revenue Estimates
Lexicon (LXRX) delivered earnings and revenue surprises of 0.00% and -88.73%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Earnings Preview: Ovid Therapeutics (OVID) Q2 Earnings Expected to Decline
Ovid Therapeutics (OVID) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
Ovid Therapeutics (OVID) Appoints Kevin Norrett as Chief Business Officer
Ovid Therapeutics (OVID) Appoints Kevin Norrett as Chief Business Officer...
Yahoo! Finance: News
Ovid Therapeutics (OVID) to Release Earnings on Tuesday
Ovid Therapeutics (NASDAQ:OVID) will be releasing its Q1 2026 earnings before the market opens on Tuesday, May 12. (View Earnings Report at...
MarketBeat
Ovid Therapeutics (NASDAQ:OVID) Sees Large Decline in Short Interest
Ovid Therapeutics (NASDAQ:OVID - Get Free Report) saw a significant decline in short interest during the month of April. As of April 15th, there was short interest totaling 6,957,013 shares, a decline of 25.5% from the March 31st total of 9,337,824 shares. Based on an average trading volume of...
MarketBeat
Ovid Therapeutics (NASDAQ:OVID) Given Average Recommendation of "Buy" by Analysts
Shares of Ovid Therapeutics (NASDAQ:OVID - Get Free Report) have been assigned an average rating of "Buy" from the ten research firms that are covering the firm, MarketBeat.com reports. One research...
MarketBeat
Ovid Therapeutics' (OVID) "Outperform" Rating Reiterated at Wedbush
Wedbush reiterated an "outperform" rating and issued a $7.00 price target on shares of Ovid Therapeutics in a report on Wednesday...
MarketBeat
Short Interest in Ovid Therapeutics (NASDAQ:OVID) Increases By 71.2%
Ovid Therapeutics (NASDAQ:OVID - Get Free Report) saw a large increase in short interest during the month of March. As of March 31st, there was short interest totaling 9,337,824 shares, an increase...
MarketBeat
HC Wainwright Issues Positive Forecast for OVID Earnings
Ovid Therapeutics (NASDAQ:OVID - Free Report) - Equities research analysts at HC Wainwright boosted their Q2 2026 earnings per share (EPS) estimates for Ovid Therapeutics in a research note issued on...
MarketBeat

Advertisement|Remove ads.